Precision BioSciences (NASDAQ:DTIL) Given “Buy” Rating at HC Wainwright

Precision BioSciences (NASDAQ:DTIL)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $60.00 price target on the stock.

Separately, BMO Capital Markets raised Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price target on the stock in a report on Friday, January 10th.

Precision BioSciences Price Performance

NASDAQ DTIL opened at $5.36 on Wednesday. The business’s fifty day moving average price is $5.15 and its 200-day moving average price is $6.77. The stock has a market capitalization of $41.12 million, a price-to-earnings ratio of 89.35 and a beta of 1.59. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22. Precision BioSciences has a 1-year low of $3.61 and a 1-year high of $15.97.

Insider Activity

In related news, CEO Michael Amoroso sold 36,838 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $4.67, for a total value of $172,033.46. Following the transaction, the chief executive officer now directly owns 107,087 shares of the company’s stock, valued at approximately $500,096.29. This trade represents a 25.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider J. Jefferson Smith sold 10,287 shares of the firm’s stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $4.79, for a total value of $49,274.73. Following the completion of the transaction, the insider now directly owns 87,440 shares in the company, valued at approximately $418,837.60. This represents a 10.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have bought 8,734 shares of company stock valued at $39,946 and have sold 47,279 shares valued at $222,064. Insiders own 4.00% of the company’s stock.

Hedge Funds Weigh In On Precision BioSciences

A number of institutional investors have recently bought and sold shares of DTIL. Lynx1 Capital Management LP bought a new position in Precision BioSciences in the 4th quarter worth $2,919,000. Janus Henderson Group PLC raised its holdings in Precision BioSciences by 10.9% during the third quarter. Janus Henderson Group PLC now owns 702,069 shares of the company’s stock valued at $6,322,000 after acquiring an additional 68,943 shares during the period. Citadel Advisors LLC raised its holdings in Precision BioSciences by 58.0% during the fourth quarter. Citadel Advisors LLC now owns 153,675 shares of the company’s stock valued at $586,000 after acquiring an additional 56,400 shares during the period. Moloney Securities Asset Management LLC raised its holdings in Precision BioSciences by 177.0% during the fourth quarter. Moloney Securities Asset Management LLC now owns 87,799 shares of the company’s stock valued at $335,000 after acquiring an additional 56,100 shares during the period. Finally, Dimensional Fund Advisors LP bought a new stake in Precision BioSciences during the fourth quarter valued at about $211,000. 37.99% of the stock is owned by institutional investors.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.